Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Laurens who wrote (689)	5/20/1999 1:25:00 PM
From: Laurens	Read Replies (1) \| Respond to of 900

Lipo steaming ahead. Gaining $2 this week. Nearing 52 week high of 16 7/8 Fasten seatbelts! Go Lipo.

To: Laurens who wrote (689)	6/4/1999 6:29:00 PM
From: Cheeseburger	Read Replies (2) \| Respond to of 900

LIPO is "A Biotech About to Bloom" David Moskowitz, of Standard & Poor's The Outlook, says Liposome (LIPO) is a biotech stock about to bloom. The company is a leader in using liposomal technology (chemicals trapped in fat molecules) to lower drug toxicity. Abelcet, the firm's first product, treats systemic fungal infections while Evacet, a liposomal form of the widely used anticancer agent doxorubicin, is now under FDA review. "We anticipate a positive recommendation, which should lead to approval by year-end," Moskowitz says. "If given the green light, Evacet will be sold in the billion dollar breast cancer drug market." Moskowitz says Liposome is the right kind of biotech drug company -- "one with late-stage or currently marketed products entering large markets where therapeutic improvements are needed." Liposome is already past the arduous and failure-ridden development stage, and the return on investment at this stage is much closer. He goes on to say that late-stage companies are prime acquisition targets for larger drug companies. "With solid management, a proven technology platform and favorable news expected, the shares have significant upside potential," Moskowitz says, adding that a potential takeover adds to the stock's "speculative appeal."